» Articles » PMID: 19828560

Lack of Prophylaxis Before the Onset of Acute Venous Thromboembolism Among Hospitalized Cancer Patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER)

Overview
Journal Ann Oncol
Publisher Elsevier
Specialty Oncology
Date 2009 Oct 16
PMID 19828560
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Venous thromboembolism (VTE) prophylaxis remains underutilized, particularly in cancer patients. We explored clinical predictors of prophylaxis in hospitalized cancer patients before the onset of acute VTE.

Methods: In the SWiss Venous ThromboEmbolism Registry, 257 cancer patients (61 +/- 15 years) with acute VTE and prior hospitalization for acute medical illness or surgery within 30 days (91% were at high risk with Geneva VTE risk score > or =3) were enrolled.

Results: Overall, 153 (60%) patients received prophylaxis (49% pharmacological and 21% mechanical) before the onset of acute VTE. Outpatient status at the time of VTE diagnosis [odds ratio (OR) 0.31, 95% confidence interval (CI) 0.18-0.53], ongoing chemotherapy (OR 0.51, 95% CI 0.31-0.85), and recent chemotherapy (OR 0.53, 95% CI 0.32-0.88) were univariately associated with the absence of VTE prophylaxis. In multivariate analysis, intensive care unit admission within 30 days (OR 7.02, 95% CI 2.38-20.64), prior deep vein thrombosis (OR 3.48, 95% CI 2.14-5.64), surgery within 30 days (OR 2.43, 95% CI 1.19-4.99), bed rest >3 days (OR 2.02, 95% CI 1.08-3.78), and outpatient status (OR 0.38, 95% CI 0.19-0.76) remained the only independent predictors of thromboprophylaxis.

Conclusions: Although most hospitalized cancer patients were at high risk, 40% did not receive any prophylaxis before the onset of acute VTE. There is a need to improve thromboprophylaxis in cancer patients, particularly in the presence of recent or ongoing chemotherapy.

Citing Articles

A Three-year Retrospective Study Looking at Preventing Hospital Acquired Thrombosis.

Kammath V, Gupta A, Bald A, Hope G, Kansal N, Al Samaraee A Cardiovasc Hematol Agents Med Chem. 2024; 22(2):212-222.

PMID: 38288832 DOI: 10.2174/0118715257269027231228114930.


A Rare Presentation of Acute Kidney Injury in Diffuse Large B-Cell Lymphoma: A Case Report.

Saleh M, Salih N, Kakakhel M, Ullah I, Siraj H, Tariq M Cureus. 2023; 15(9):e45642.

PMID: 37868496 PMC: 10589075. DOI: 10.7759/cureus.45642.


Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology).

Munoz-Langa J, Jimenez-Fonseca P, Carmona-Bayonas A, de Castro E, Perez-Segura P, Canovas M Clin Transl Oncol. 2020; 23(4):799-811.

PMID: 32789772 DOI: 10.1007/s12094-020-02472-x.


Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist's impact on anticoagulant therapy.

Kandemir E, Bayraktar-Ekincioglu A, Kilickap S Support Care Cancer. 2020; 29(3):1699-1709.

PMID: 32776163 DOI: 10.1007/s00520-020-05669-6.


Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience.

Figueroa R, Alfonso A, Lopez-Picazo J, Gil-Bazo I, Garcia-Mouriz A, Hermida J Clin Transl Oncol. 2018; 21(6):805-809.

PMID: 30446983 DOI: 10.1007/s12094-018-1986-1.